Use of gemcitabine (GEM) in advanced myelodysplastic syndromes [2]

Annals of Oncology

Volumn 12, Issue 10, 2001, Pages 1494-

  Di Mario, A ^a   Pagano, L ^a   Mele, L ^a   Stefano, V De ^a   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GEMCITABINE; IDARUBICIN;

ADVANCED CANCER; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROPOIESIS; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LETTER; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035179526     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012594004015     Document Type: Letter

References (5)

1. Myelodysplasia
2. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome
3. Decreased resistance to gemcitabine (2′, 2′-difluorodeoxycytidine) or cytosine arabinoside-resistant myeloblastic murine and rat leukaemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase
4. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus ara-C on blast cell from patients with blast crisis chronic myeloproliferative disorders
5. Report of an international working group to standardize response criteria for myelodysplastic syndromes